Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONT-10 and Varlilumab in Advanced Ovarian or Breast Cancer
NCT02270372Phase 1Completed
- Sponsor
- Cascadian Therapeutics
- Start
- Nov 2014
- Primary completion
- Jun 2016
- Modality
- Antibody Conjugates, Targeted Liposomes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONT-10 and varlilumab in breast cancer and ovarian cancer, sponsored by Cascadian Therapeutics. Primary endpoint: Number of participants with adverse events as a measure of safety and tolerability. Started Nov 2014; status: completed.
02
Drugs
ONT-10varlilumab
03
Conditions
breast cancerovarian cancer
Beyond the preview
Go deeper on NCT02270372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02270372.